Abstract
Objective
To determine the frequency of selected serum autoantibodies and their clinical associations in patients with childhood-onset (ChO) or adult-onset (AO) linear scleroderma (LiScl) evaluated at a single institution.
Methods
Seventy-two patients (ChO = 40, AO = 32), including 12 with en coup de sabre, were studied. All ChO patients had disease onset before age 16 years. Clinical features (extent of cutaneous disease, activity, and joint contractures) were recorded. Antinuclear antibodies (ANA) were identified by indirect immunofluorescence (HEp-2 cells), and anti-single-stranded DNA (anti-ssDNA), antihistone (AHA), and antichromatin (AChA) autoantibodies were detected by ELISA.
Results
There were no significant differences between groups in regard to gender, proportion with LiScl/E, or clinical features except joint contractures (ChO > AO; p = 0.04). There were no differences in the frequency of ANA or other autoantibodies between the groups except for AHA (ChO > AO). AHA was more frequently found with anti-ssDNA (p < 0.0001). LiScl patients with positive anti-ssDNA and/or AHA had more extensive cutaneous involvement and more often had joint contractures (p < 0.05). Anti-ssDNAwas present more frequently inAO than in ChO patients with active lesions (p = 0.04). ANA and AChA were not associated with any clinical features. Both AHA and anti-ssDNA levels showed good correlation with disease severity.
Conclusion
Over two-thirds of LiScl patients had ANA. Patients with ChO were similar to those with AO with regard to the frequency of selected serum autoantibodies. Anti-ssDNA and AHA were frequently found together and both were associated with more extensive skin disease with joint contractures. LiScl disease severity correlated with the serum levels of both these antibodies.
Key Indexing Terms:Footnotes
-
T. Arkachaisri, MD, Assistant Professor of Pediatrics, Division of Rheumatology, Children’s Hospital of Pittsburgh and Department of Pediatrics, University of Pittsburgh School of Medicine; N. Fertig, Research Technician, University of Pittsburgh School of Medicine; S. Pino, MD, Clinical Fellow, Division of Rheumatology, Children’s Hospital of Pittsburgh and Department of Pediatrics, University of Pittsburgh School of Medicine; T.A. Medsger Jr, MD, Professor of Medicine, University of Pittsburgh School of Medicine.
-
Supported by the Scleroderma Research Fund; University of Pittsburgh School of Medicine; Scleroderma Foundation (National Registry for Childhood Onset Scleroderma), Peabody, Massachusetts; Zale Foundation, Dallas, Texas; and Taub Fund, Chicago, Illinois.
- Accepted for publication August 25, 2008.